# University of Texas at Tyler

# Scholar Works at UT Tyler

**MSN Capstone Projects** 

Nursing

Fall 11-27-2023

# Vaginal Preparation in Cesarean Delivery to Decrease Surgical Site Infections: A Benchmark Study

Angelica Ware aware8@patriots.uttyler.edu

Follow this and additional works at: https://scholarworks.uttyler.edu/nursing\_msn

Part of the Female Urogenital Diseases and Pregnancy Complications Commons, Nursing Commons, and the Skin and Connective Tissue Diseases Commons

#### **Recommended Citation**

Ware, Angelica, "Vaginal Preparation in Cesarean Delivery to Decrease Surgical Site Infections: A Benchmark Study" (2023). *MSN Capstone Projects*. Paper 284. http://hdl.handle.net/10950/4510

This MSN Capstone Project is brought to you for free and open access by the Nursing at Scholar Works at UT Tyler. It has been accepted for inclusion in MSN Capstone Projects by an authorized administrator of Scholar Works at UT Tyler. For more information, please contact tgullings@uttyler.edu.

Vaginal Preparation in Cesarean Delivery to Decrease Surgical Site Infections: A Benchmark

Study

A Paper Submitted in Partial Fulfillment of the Requirements

For NURS 5382: Capstone

In the School of Nursing

The University of Texas at Tyler

by

Angelica Ware

December 4, 2023

# **Contents**

# Acknowledgments

# **Executive Summary**

# **Implementation and Benchmark Project**

- 1. Rationale for the Project
- 2. Literature Synthesis
- 3. Project Stakeholders
- 4. Implementation Plan
- 5. Timetable/Flowchart
- 6. Data Collection Methods
- 7. Evaluation
- 8. Cost/Benefit Analysis
- 9. Discussion of Results

Conclusions/Recommendations

References

Appendices

## Acknowledgments

First and foremost, I would like to praise God for giving me the willpower to achieve my master's. God has and will always be the foundation in my life that provides strength, courage, and immense love. Thank you, Jesus, for all you have done for me and all you will do for me.

To my friends and family, words cannot express my gratitude for each of you. I would not have accomplished the things in my life without your support. This achievement, along with many others, is my success and yours. I would not be here without your grace, love, patience, willingness, and sacrifice. Thank you for believing and trusting me throughout this entire process. I cannot put into words how grateful I am, but know that I am beyond thankful.

To my number one fan, my rock, my world, Jordan, I love you. You will be old enough to read this one day, and I hope you are proud. Although you may not know, you are my reason, the driving force for my motivation. During this time, you have been kind and patient towards me. Thank you for giving me hope, pushing me to new limits, and allowing me to lead by example. You are the world's most incredible son and will forever be my baby.

To the staff at The University of Texas at Tyler, thank you. Your contribution does not go unnoticed. The compassion I have experienced during my academic career will forever impact me. My undergraduate and graduate professors have given me the tools needed to be a good nurse and leader. Thank you for your inspiration.

## **Executive Summary**

This benchmark project intends to decrease the rate of surgical site infections related to cesarean procedures with vaginal preparation through an evidence-based approach. *Vaginal preparation* is a simple technique that cleanses the vaginal walls by removing microorganisms. The goal of the benchmark project is to promote the implementation of a vaginal preparation policy across any healthcare facility that performs cesarean procedures. Vaginal preparation is intended for scheduled cases, add-on cases, and urgent cases. The benchmark study does not include emergent cesarean deliveries, as vaginal preparation is at the discretion of the physician in those cases.

The topic of surgical site infections has been around for more than a decade. However, with the increasing number of cesarean deliveries, the rate of surgical site infections is also increasing. Many efforts have been made to decrease the incidence of surgical site infections in cesarean delivery; however, evidence shows that further work is still needed. Improved operating room ventilation, sterilization methods, barriers, surgical techniques, and antimicrobial prophylaxis are advances that have been made to promote infection control (ACOG, 2018).

According to Berríos-Torres et al., (2017), approximately half of surgical site infections are deemed preventable using evidence-based strategies.

In 2021, approximately 1,174,545 babies were born in the United States via cesarean delivery (Osterman et al., 2023). Although most who undergo the procedure do not face complications, a significant percentage do. One of the complications associated with cesarean deliveries is surgical site infections post-delivery. Maternal sepsis is a life-threatening condition that causes systemic organ dysfunction during pregnancy, birth, post-abortion, and post-partum (World Health Organization, 2021). Infections that are related to maternal sepsis include but are

not limited to infection at the surgical site, urinary tract infections, and endometritis (World Health Organization, 2021). Exploring solutions to surgical site infections post-cesarean delivery is essential. There is great significance in skin preparation technique, duration, and dry time prior to the start of cesarean delivery. Perhaps, if the focus shifted to a combination of skin and vaginal preparation, the rate of surgical site infections would decrease. The developed PICOT question for the benchmark is: In patients undergoing cesarean delivery (P) how does vaginal preparation (I) compared to no vaginal preparation (C) impact surgical site infections (O) within a three-month timeframe (T)?

# Vaginal Preparation in Cesarean Delivery to Decrease Surgical Site Infections

Imagine presenting to the hospital for a scheduled repeat cesarean delivery to a beautiful baby and, seventeen days later, being told a complication occurred. One could not help but wonder if everything was done to prevent the potential complication. This benchmark study explores the impact of vaginal preparation prior to cesarean deliveries. There is mounting evidence for the effectiveness of vaginal preparation and increased awareness of surgical site infections; however, it is unclear why this simple technique has not become a standard of care (Duffy et al., 2019).

# **Rationale for the Project**

In the United States, cesarean delivery is the most common major surgical procedure, with nearly one in every three neonates delivered by cesarean (Duffey et al., 2019). Infectious morbidity post-cesarean delivery is a major health problem. The effects can lead to maternal health morbidities in addition to economic burden (Aref, 2019). Despite healthcare professionals' commitment to the care and improvement of human life, unfortunate and unpredictable events still occur. Every woman's childbirth experience is unique, and many factors, direct and indirect, can influence patients' perspectives. There is great importance in patients' experience while receiving medical treatment, especially during childbirth. The experiences during childbirth can be considered life-changing and have great significance on patients' perception of the healthcare system. The mistreatment of women during childbirth is a violation of women's fundamental human rights (Nilvér et al., 2017). Mistreatment can occur between the woman and health care provider and through systematic failures in health facilities and health systems (Nilvér et al., 2017). It is vital to ensure the trust of the maternal population, continuation of patient outcome improvement, and enhance the quality of care.

## **Literature Synthesis**

Surgical site infections are a common complication that can happen after any surgical procedure. Recently, surgical site infections related to cesarean delivery have increased. Over the years, relentless efforts have been made to find an effective solution. For this benchmark study, twelve studies were identified to support the need for vaginal preparation before cesarean procedures. The evidence for the benchmark study includes a quasi-experimental study, systematic review, meta-analysis, quality improvement report, and randomized control trials. The research illustrates a compelling argument on why vaginal preparation is vital before cesarean delivery and how it can be accomplished.

Of the twelve selected studies, eleven found that vaginal preparation reduces infectious morbidity, endometritis, fever, and wound infection in patients undergoing a cesarean procedure (Ahmed et al., 2017; Fadlalmola et al., 2022; Guzman et al., 2002; Hass et al., 2020; Jakes et al., 2020; Kanza, 2021; Kawakita et al., 2019; Lakhi et al., 2019; Liu et al., 2023; Ogah et al., 2021; Roeckner et al., 2019). One study suggests further research is needed to definitively recommend vaginal preparation prior to cesarean delivery (Reid et al., 2001).

Different methods of vaginal preparation were completed throughout the evidence.

Fadlalmola et al., (2022) states that povidone-iodine had the highest reduction of only endometritis. In contrast, Roeckner et al., (2019) argues that povidone-iodine effectively reduces the rate of endometritis, wound infection, and post-operative fever rates. However, Fadlalmola et al., (2022) claims chlorhexidine and normal saline are more effective for reducing wound infection, fever, and hospital duration. Nevertheless, Kanza (2019) states that vaginal preparation with normal saline or povidone-iodine significantly reduces post-operative pain, fever, CRP levels, endometritis, and surgical site infections. Furthermore, wound infection was significantly

lower with chlorhexidine compared to povidone-iodine in patients undergoing cesarean delivery. (Lakhi et al., 2019). Four of the twelve studies did not decipher specific cleansing agents for vaginal preparation but found an overall reduction in surgical site infections (Ahmed et al., 2017; Hass et al., 2020; Liu et al., 2023; Ogah et al., 2021).

A quality improvement project was implemented for a year at a large hospital and was found to reach the lowest rate of surgical site infections in the last six years (Jakes et al., 2020). One study utilized a surgical bundle that included vaginal preparation to decrease surgical site infections in cesarean deliveries (Kawakita et al., 2019). Additionally, two studies (Ahmed et al., 2017 & Ogah et al., 2021) utilized a control and intervention group, which found a reduction for the intervention group. Infectious morbidity in the control group was reduced from 24.4% to 8.8% in the intervention group (Ahmed et al., 2017). Consequently, the control group in Ogah et al., (2021) had a reduction in infectious morbidity from 36.8% (control) to 12.0% (intervention).

# **Project Stakeholders**

The benchmark study includes many stakeholders. The chief nursing officer (CNO), director of women's services, unit manager, and policymakers will be involved in the decision-making process. The facilities' process and procedures impact the success of the benchmark study, along with the organizations' culture towards evidence-based practice. Each stakeholder is expected to participate in the benchmark study and provide critical elements. Other stakeholders include allied health professionals, regulatory representatives, and insurance companies. The nurse educator, a supply chain member, and certified scrub technicians will also be involved in the benchmark study. The key stakeholders for the benchmark study are patients, staff nurses, vaginal preparation super users, charge nurses, and evidence-based practice mentors.

#### **Implementation Plan**

The need for this project is derived from a synopsis of the synthesized data. Increased surgical site infections in obstetrics can be decreased with improvements in pre-delivery hygiene. Implementation will be conducted in different phases. First, collaboration will be established between administrators, clinicians, and staff. The specific goal of decreasing surgical site infections by performing a vaginal cleansing before cesarean delivery will be emphasized. Everyone involved must agree on the goal of the project. Vaginal preparation before cesarean delivery will be carried out on the OB/GYN unit at a large metropolitan acute care hospital. Second, permission will be obtained for the benchmark project from the women services director. Gaining administrative support will play a vital role in the success of implementation.

Gathering other allies who support and help with vaginal preparation before cesarean deliveries will be beneficial. The perinatal program manager, chief obstetrician and gynecologist, and clinical educator will have recourse to the implementation phase. Understanding the organization's day-to-day workflow is vital to implementing a new process. Collaborating with the manager will provide effective communication between individuals carrying out vaginal preparation prior to cesarean deliveries.

Prior to implementation, data will be collected that includes a combination of total cesarean deliveries, post-delivery fevers, prolonged hospital stays due to antibiotic therapy, surgical site infection readmits, and cases of maternal sepsis that require a transfer to a higher level of care. A chart of the difference in cost for someone who acquires a surgical site infection versus someone who does not will be created. This data provides evidence of the need for this benchmark project and will be available to personnel interested in reading the research.

After receiving authorization for the benchmark project, A presentation reflecting the need to foster evidence-based practice in the clinical environment will be presented to the unit.

Vaginal preparation education, instructions, necessary resources, and expectations of the project will also be provided. To increase staff knowledge, communication of the project will include an organizational email and also be presented during staff meetings. Included in the instructional materials will be a patient scenario (including graphic images) with maternal sepsis. This will motivate staff to implement vaginal preparation. To foster a smooth and effective transition, collaboration with unit staff members will be utilized to focus on the ultimate goal. Not only does collaborating with unit members promote teamwork, but it also provides an opportunity for feedback.

A mandatory in-service session with a manufacturer representative and an online health stream module will be required. The in-service sessions will be available to night and day shifts at varying times. The due date for the online education module will be prior to the start date of implementation. To ensure staff are competent with vaginal preparation, every employee will need a skills check-off. Flyers will be posted around the unit identifying the skills check-off and in-service complementation deadline. Vaginal preparation will also be required in the annual ongoing competencies skills check-off.

The cleansing agent must be added to the unit supply room prior to the start date. The specific quantity will depend on how many cesarean deliveries are completed on average per month and how many cleansing agents will be required per patient. However, the location of the solution will be discussed and shown during the check-off.

Following the start date, establishing compliance is key. The ultimate goal of compliance is ninety percent or greater during implementation. In addition, creating a documentation tool for vaginal preparation must be designed. It is essential to consider whether the tool is on paper or within the software during implementation. Next, the documentation expectation will be

announced to staff members to avoid compliance fallouts. To ensure staff compliance, vaginal preparation will be added to the pre-operation checklist, and super users will be on the unit to enforce compliance. Chart audits will be conducted at random, and missed opportunities will result in verbal coaching to recurrent offenders.

Finally, one must anticipate barriers to implementing vaginal preparation prior to cesarean deliveries. Although vaginal preparation can be accomplished within minutes, some physicians with weak beliefs about the value of evidence-based practice may opt to give a verbal order to bypass the vaginal cleansing step. In an attempt to avoid this barrier, physicians will be provided with data that supports the benchmark project. The final approach to minimizing the barrier is to empower the nursing staff to utilize the CUS communication tool. Nurses can express concern about not completing the required vaginal preparation by stating that they are uncomfortable. Deliberately skipping over vaginal preparation can be identified as a patient safety violation and ultimately put the patient at risk for surgical site infection. It is imperative to not only support staff members throughout the change but also walk through the change process with them.

Patients' electronic medical records will be reviewed to analyze the benchmark project results. However, informed consent, a HIPAA authorization, and an approved waiver must be obtained first. After access has been granted, medical records will be sorted, and data will be attained. During the results collection, post-partum readmits and patients with signs/symptoms of post-operative surgical site infection will be sought out. Surgical site infection includes redness, swelling, discharge, unusual pain at the incision site, and fever. Chart reviews will occur weekly for the remainder of the benchmark project.

#### Timetable/Flowchart

The benchmark study will be conducted over fifteen weeks. Each week will have a designated task to be completed to ensure the steps are completed on time. First, the data will be reviewed, and a project blueprint will be created. These two components should be completed within the first two weeks of the study. Evidence will be presented to stakeholders, and approval will be gained. Next, an implementation plan strategy will be created and executed. Each specific detail will be conducted in a step-by-step manner. Two weeks will be focused on providing vaginal preparation education. Vaginal preparation will go live the following week and be continued for three months. Next, enforcing compliance will occur. After compliance is established, data will be gathered. Data review will be conducted next, and the results will be provided to stakeholders. Finally, the results will be disseminated into practice, and standard practice will be changed.

#### **Data Collection**

After completing the benchmark study, data will be collected for six months following implementation. The collection method for the benchmark study includes chart reviews and audits. The patient and facility will grant access to the electronic medical record prior to the start of data collection. To determine if vaginal preparation was successful in reducing surgical site infections, specific criteria will be assessed. An Excel spreadsheet will be utilized to sort and contain the data collected. Included in the spreadsheet will be the patient's initials, date of cesarean delivery, vaginal preparation agent and technique (if applicable), length of hospital duration, hospital readmission, surgical site infection symptoms, and antibiotic therapy. Vaginal preparation, length of hospital duration, and date of delivery will be available within a week of the procedure. Hospital readmission, surgical site infection symptoms, and antibiotic therapy may occur within thirty days of the procedure. Each chart will be assessed for fever, complaints

of purulent discharge, redness, unusual incision pain, and swelling. Suppose antibiotic therapy is utilized in the post-partum period. In that case, further examination will determine if it results from a surgical site infection or if the antibiotic was used to treat other conditions, such as chorioamnionitis. A second analyzer will review the collected data to ensure all information is received and all components are adequately reviewed.

#### **Evaluation**

Comparing the rates of surgical site infections in patients who received vaginal preparation compared to those who did not will then take place. Vaginal preparation will be considered effective if there is either a decrease in patients with post-operative fever, antibiotic use, and infection symptoms. Once vaginal preparation has been declared effective in the reduction of surgical site infections, dissemination of this knowledge will begin.

## **Cost/Benefit Analysis**

According to de Lissovoy et al. (2009), hospital-acquired infections are among the top ten leading causes of death in the United States of America. Of the hospital-acquired infections, more than 20% are attributed to surgical site infections (de Lissovoy et al., 2009). From a national perspective, surgical site infections were associated with an additional 406,730 hospital days and costs exceeding \$900 million (de Lissovoy et al., 2009). Implementing vaginal preparation before cesarean delivery is estimated to be low costing and within budget. Although the actual cost is currently unavailable, the anticipated price is low. A pre-operative vaginal cleansing agent is far less expensive than the associated costs of surgical site infection. Due to the risks associated with surgical site infections, the cost of a vaginal preparation agent should not be in great question. Surgical site infections represent financial and opportunity costs to

hospitals and suggest, along with the implication for patient care, a continuing need for cost-effective quality improvement and infection prevention programs (Boltz et al., 2011).

In addition to the financial cost, surgical site infections impact patients' quality of care, especially in new mothers. Increased pain and temporary loss of function can hinder the ability of a new mother to care for and bond with her baby. The post-partum period can be a challenging experience even if no complications arise. Adding surgical site infections during the post-partum period adds a new level of stress and anxiety. Surgical site infection is a burden for the patient and has a relevant impact on the patient's satisfaction with healthcare (Strobel et al., 2022).

#### **Discussion of Results**

Implementing the benchmark study was not feasible due to the short time frame of the academic semester. Patient and facility approval for chart review required a significant length of time and would not be possible. Although it remains uncertain, the benchmark study is expected to be successful in the reduction of surgical site infections. There is an abundance amount of solid evidence that supports vaginal preparation prior to cesarean procedures. After vaginal preparation is implemented into standard practice, the goal will be to sustain and make adjustments as needed.

The best leadership strategy for the benchmark study is transformational leadership.

Promoting vaginal preparation before cesarean deliveries is valuable and creates positive change.

Utilizing influence, inspiration, motivation, and individual consideration is vital to the benchmark study. The goal will be to utilize the benchmark study as an example to empower future leaders to promote change through evidence-based practice. A small group of individuals who are passionate about evidence-based practice and procedures will be formulated with the hope of continuing to improve patient outcomes and adjusting practice standards.

## **Conclusions/Recommendations**

Surgical site infections related to cesarean deliveries are a growing concern in today's world and warrant an immediate practice change. Surgical site infections are costly, increase patient mortality, increase hospital admission duration, and negatively affect patients' perspectives. Vaginal preparation has been proven to decrease the incidence of surgical site infection and improve patient outcomes. This benchmark study, along with other evidence, supports the need to implement vaginal preparation into standard practice. Further research is needed to explore vaginal preparation techniques and specific solution agents that are the most effective. Although rare and very unlikely, further research is also indicated to determine if vaginal preparation has any possible harmful side effects.

There is hope for the future with surgical site infections related to cesarean deliveries. Now is the opportunity to make a difference, advocate for our patients, and improve outcomes. The objective is to apply vaginal preparation into standard practice with the hopes of decreasing surgical site infections.

## References

- ACOG committee opinion no. 750 summary: perioperative pathways: enhanced recovery after surgery. (2018). *Obstetrics and Gynecology*, *132*(3), 801–802. <a href="https://doi.org/10.1097/AOG.0000000000002819">https://doi.org/10.1097/AOG.000000000000002819</a>
- Ahmed, M. R., Aref, N. K., Sayed Ahmed, W. A., & Arain, F. R. (2017). Chlorhexidine vaginal wipes prior to elective cesarean section: does it reduce infectious morbidity? A randomized trial. *The Journal of Maternal-Fetal & Neonatal Medicine*, 30(12), 1484–1487. https://doi.org/10.1080/14767058.2016.1219996
- Aref, N. K. (2019). Vaginal cleansing prior to caesarian section: To do or not to do?: A randomized trial. *Journal of Gynecology Obstetrics and Human Reproduction*, 48(1), 65–68. <a href="https://doi.org/10.1016/j.jogoh.2018.11.002">https://doi.org/10.1016/j.jogoh.2018.11.002</a>
- Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D. W., Leas, B., Stone, E. C., Kelz, R. R.,
  Reinke, C. E., Morgan, S., Solomkin, J. S., Mazuski, J. E., Dellinger, E. P., Itani, K. M.
  F., Berbari, E. F., Segreti, J., Parvizi, J., Blanchard, J., Allen, G., Kluytmans, J. A. J. W.,
  Donlan, R., ... Healthcare Infection Control Practices Advisory Committee. (2017).
  Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. *JAMA Surgery*, 152(8), 784–791.
  <a href="https://doi.org/10.1001/jamasurg.2017.0904">https://doi.org/10.1001/jamasurg.2017.0904</a>
- Boltz, M. M., Hollenbeak, C. S., Julian, K. G., Ortenzi, G., & Dillon, P. W. (2011). Hospital costs associated with surgical site infections in general and vascular surgery patients. *Surgery*, 150(5), 934–942. https://doi.org/10.1016/j.surg.2011.04.006

- de Lissovoy, G., Fraeman, K., Hutchins, V., Murphy, D., Song, D., & Vaughn, B. B. (2009).

  Surgical site infection: incidence and impact on hospital utilization and treatment costs.

  American Journal of Infection Control, 37(5), 387–397.

  <a href="https://doi.org/10.1016/j.ajic.2008.12.010">https://doi.org/10.1016/j.ajic.2008.12.010</a>
- Duffy, C. R., D'Alton, M. E., Han, Y. W., Goldenberg, R. L., & Gyamfi-Bannerman, C. (2019).
  Incorporating precesarean vaginal preparation into standard of care for obstetrics.
  Obstetrics and Gynecology, 133(4), 707–711.
  <a href="https://doi.org/10.1097/AOG.0000000000003153">https://doi.org/10.1097/AOG.00000000000003153</a>
- Fadlalmola, H. A., Al-Sayaghi, K. M., Al-Hebshi, A. A., Alshengeti, A. M., Almohammadi, N. H., Alawfi, A. D., Aljohani, M. M., & Elhaddad, N. F. (2022). Vaginal preparation with different antiseptic solutions before cesarean section for preventing postoperative infections: A systematic review and network meta-analysis. *The Journal of Obstetrics and Gynaecology Research*, 48(11), 2659–2676. <a href="https://doi.org/10.1111/jog.15377">https://doi.org/10.1111/jog.15377</a>
- Guzman, M. A., Prien, S. D., & Blann, D. W. (2002). Post-cesarean related infection and vaginal preparation with povidone–iodine revisited. *Primary Care Update for Ob/Gyns*, 9(6), 206–209. <a href="https://doi.org/10.1016/S1068-607X(02)00119-1">https://doi.org/10.1016/S1068-607X(02)00119-1</a>
- Haas, D. M., Morgan, S., Contreras, K., & Kimball, S. (2020). Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. *The Cochrane Database of Systematic Reviews*, 4(4), CD007892. <a href="https://doi.org/10.1002/14651858.CD007892.pub7">https://doi.org/10.1002/14651858.CD007892.pub7</a>

- Jakes, A. D., Bell, A., Chiwera, L., & Lloyd, J. (2020). Implementation of vaginal preparation prior to caesarean section. *BMJ Open Quality*, 9(3), e000976.
  <a href="https://doi.org/10.1136/bmjoq-2020-000976">https://doi.org/10.1136/bmjoq-2020-000976</a>
- Kanza, D. (2021). The effect of vaginal cleansing performed with normal saline solution or povidone-iodine before elective caesarean section on postoperative maternal morbidity and infection; A prospective randomized controlled study. *Marmara Medical Journal*, 34 (1), 33-39. DOI: 10.5472/marumj.866504
- Lakhi, N. A., Tricorico, G., Osipova, Y., & Moretti, M. L. (2019). Vaginal cleansing with chlorhexidine gluconate or povidone-iodine prior to cesarean delivery: A randomized comparator-controlled trial. *American Journal of Obstetrics & Gynecology MFM*, *1*(1), 2–9. <a href="https://doi.org/10.1016/j.ajogmf.2019.03.004">https://doi.org/10.1016/j.ajogmf.2019.03.004</a>
- Liu, G., Liang, J., Bai, L., Dou, G., Tan, K., He, X., Zhang, J., Ma, X., & Du, X. (2023).
   Different methods of vaginal preparation before cesarean delivery to prevent postoperative infection: A systematic review and network meta-analysis. *American Journal of Obstetrics & Gynecology MFM*, 5(8), 100990.
   <a href="https://doi.org/10.1016/j.ajogmf.2023.100990">https://doi.org/10.1016/j.ajogmf.2023.100990</a>

- Nilvér, H., Begley, C., & Berg, M. (2017). Measuring women's childbirth experiences: A systematic review for identification and analysis of validated instruments. *BMC*Pregnancy and Childbirth, 17(1), 203. https://doi.org/10.1186/s12884-017-1356-y
- Ogah, C. O., Anikwe, C. C., Ajah, L. O., Ikeotuonye, A. C., Lawani, O. L., Okorochukwu, B. C., Ikeoha, C. C., & Okoroafor, F. C. (2021). Preoperative vaginal cleansing with chlorhexidine solution in preventing post-cesarean section infections in a low resource setting: A randomized controlled trial. *Acta Obstetricia et Gynecologica Scandinavica*, 100(4), 694–703. https://doi.org/10.1111/aogs.14060
- Osterman, M. J. K., Hamilton, B. E., Martin, J. A., Driscoll, A. K., & Valenzuela, C. P. (2023).

  \*Births: Final data for 2021. National Vital Statistics Reports, 72(1), 1-53. National

  \*Center for Health Statistics. doi:https://dx.doi.org/10.15620/cdc:122047.
- Reid, V. C., Hartmann, K. E., MCMahon, M., & Fry, E. P. (2001). Vaginal preparation with povidone iodine and postcesarean infectious morbidity: A randomized controlled trial.

  \*Obstetrics and Gynecology, 97(1), 147–152. <a href="https://doi.org/10.1016/s0029-7844(00)01087-5">https://doi.org/10.1016/s0029-7844(00)01087-5</a>
- Roeckner, J. T., Sanchez-Ramos, L., Mitta, M., Kovacs, A., & Kaunitz, A. M. (2019). Povidone-iodine 1% is the most effective vaginal antiseptic for preventing post-cesarean endometritis: A systematic review and network meta-analysis. *American Journal of Obstetrics and Gynecology*, 221(3), 261.e1-261.e20.

  https://doi.org/10.1016/j.ajog.2019.04.002

- Strobel, R. M., Leonhardt, M., Förster, F., Neumann, K., Lobbes, L. A., Seifarth, C., Lee, L. D., Schineis, C. H. W., Kamphues, C., Weixler, B., Kreis, M. E., & Lauscher, J. C. (2022).

  The impact of surgical site infection-a cost analysis. *Langenbeck's Archives of Surgery*,

  407(2), 819–828. https://doi.org/10.1007/s00423-021-02346-y
- WHO recommendation on vaginal preparation with antiseptic agents for women undergoing caesarean section. (2021). World Health Organization.

Appendix A

NURS 5382 Capstone Evidence Table

Citation : (i.e., author(s ), date of publicat ion, & title)	Concept ual Framew ork	Desig n/ Meth od	Sample/ Setting	Major Variables Studied and Their Definition	Measureme nt of Major Variables	Data Analysi s	Study Findings	Strength of the Evidence (i.e., level of evidence + quality [study strengths and weaknesses])
Author, Year, Title	Theoret ical basis for study  Qualitat ive Tradition		Number, Characte ristics, Attrition rate & why?	Independ ent variables (e.g., IV1 = IV2 =)  Dependen t variables (e.g., DV = ) Do not need to put IV & DV in Legend	What scales were used to measure the outcome variables (e.g., name of scale, author, reliability info [e.g., Cronbach alphas])	What stats were used to answer the clinical question (i.e., all stats do not need to be put into the table)	Statistical findings or qualitative findings (i.e., for every statistical test you have in the data analysis column, you should have a finding)	<ul> <li>Strengths and limitations of the study</li> <li>Risk or harm if study intervention or findings implemented</li> <li>Feasibility of use in your practice</li> <li>Remember: level of evidence (See PICOT handout) + quality of evidence = strength of evidence &amp; confidence to act</li> <li>Use the USPSTF grading schema http://www.ahrq.gov/clinic/3rd uspstf/ratings.htm</li> </ul>

Ahmed et al., (2017). Chlorhe xidine vaginal wipes prior to elective cesarean section: does it reduce infectiou s morbidit y? A randomi zed trial	Evaluate PO VP with antisepti c wipes on IM rate post-CD	Rand omize d contr ol trial	pregnant women undergoi ng elective CS Term singleton pregnanci es Divided by simple randomiz ation Two different groups: study vs control	IV  CS – surgically delivery of a baby through mother's abdomen  DV  VP – cleansing intravagin ally with a solution  IM – endometrit is, would infection, febrile morbidity	Examined post-CD at time of hospital discharge and weekly till end of PP period	SPSS version 15  Qualitat ive data express ed as number s and percent ages  Student t test and x² were used	Post-CS IM were reduced from 24.4% (control group) to 8.8% (intervention group)	Level of evidence: II  Strengths: no side effects reported from VP, patients were chosen randomizied, a unique methodology manner, low cost internvetion  Limitations: during follow up 7 intervention cases and 11 control cases were lost, lack of follow up to neaonatal outcomes, small sample size  Feasibile for practice  Conclusion/recommendation: complete longitudinal study, cleansing with chlorhexidine appears to decrease endometritis rates post-CD
Fadlalm ola et al., (2022). Vaginal preparati	Investig ate effect of vaginal solution	Syste matic revie w and netwo	29 RCTs  Total sample size: 9311	IV CS - surgically delivery of a baby	Comprehens ive search retrieved 1663 records after	Used netmeta packag e in R softwar	Povidone-iodine had highest reduction of endometritis in post-CD	Level of evidence: I  Strengths: using a network framework for direct and indirect comparisons, only included clincal trials published until end

on with	s on	rk	women	through	omitting	e	Chlorhexidine	of 2021, assessed most essential
different	reducing	meta-	undergoi	mother's	429	version	and saline had	outcomes and publication bias,
antisepti	post-CD	analy	ng CD	abdomen	duplicates,	4.1.2	highest reduction	low cost intervention, cleaning
•	-	_	ing CD	abdomen	•	7.1.2		,
c solutions before cesarean section for preventing postoper ative infection s: A systematic review and network metanalysis	endomet ritis, WI, fever, hospital stay duration	sis  Acco mplis hed in agree ment with "coch rane handb ook for syste matic revie ws of interv entio ns	Patients undergoi ng CD whether elevtive, in labor, or emergent included Any VP solution included Restrided to RCTs only	VS – povidone- iodine, chlorhexii ne, saline  DV  Endometri ties, WI, fever – disease process at mircoscop ic level effecting tissues  Hospital stay duration – length of time admitted to hospital	screened titles and abstracts of 1234 records, out of 46 records 29 RCTs were included	Compar ed various solution s twice with and without account ing for dosage or concent rations  Heterog eneity assesse d using I² and p-value of chisquared test	of WI, fever, and hospital duration	Limitations: definitions of endometritis, post-CD fever and WI varied among RCTs, cannot eliminate confounding variables and selection biases, included studies that differed in type and time of administration of PO antibiotics  Feasible for practice  Conclusion/Recommendation: different vaginal solutons are associated with reduction in post-CD endometritis, WI, fever, and hospital stay duration, setting povidone-iodine as standard practice solution

Guzman et al., (2002), Post-cesarean related infection and vaginal preparati on with povidon e-iodine revisited	To ascertain whether VP with povidon e-iodine before CD would reduce incidenc e of post CS related infection s	Rand omize d, blind ed, contr olled, clinic al trial	160 subjects, 80 cases, 80 controls  Studies conducte d between March 2000 and July 2001 at Universit y	IV  VP — cleansing of vaginal walls with solution  CD — surgical procedure delivering baby via incision through abdomen  DV	VP completed by scrub nurse while physicians were scrubbing and surgeons were not informed of which patient was randomized	Egger test used  Analyz ed using Statistic al progra m for the social science s (SPSS)  version 8.0  Student t test	VP with povidine-iodine before CD can decrease post-partum morbidity associated with endometritis	Level of evidence: II  Strengths: finds appear consistent, even in patients with increased VE  Limitations: number of factors can influence infection rates  Conclusion/recommendation: VP with povidine-iodine prior to CD can decrease PP morbidity associated with endometritis, studies with larger patient populations are needed to conform obsercations
revisited	infection		at Universit	abdomen		8.0		

				ı	1	П	I	23
Hass et al., (2020),	Determi ne if cleansin	Syste matic revie	21 trials, reporting 7038	6 hrs apart, > 24 hrs post- op  IV  VP was completed	Cochrane Pregnancy and	Three of the review	VP prior to CD probably reduces the incidence of	Level of Evidence: Level I Strengths: not specified
Vaginal preparati on with antisepti c solution before cesarean section for preventing postoper ative infection s	g the vagina with an antisepti c solution before a CD decrease s risk of maternal infection Also assessed vaginal cleansin g	W	women evaluatin g effects of vaginal cleansing Included: RCTs and two quasi- RCTs Pregnant women who were about to receive a CD,	completed no more than one hour prior to the CD, VP including douches, wipes, sponges, with any type of antiseptic solution versus a placebo or no VP	Childbirth's Trials Register, World Health Organizatio n (WHO) Internationa l Clinical Trials Registry Platform and reference lists of retrieved studies	authors indepen dently assesse d eligibili ty of the studies	post CD endometritis, post op fever, and post op wound infection, no adverse effect were reported with vaginal cleansing	Limitations: not specified  Conclusion/recommendation: Further analysis suggested greater effect women in labour versus those not in labour (post- cesarean infection of uterus, post-op fever, post-op WI, wound complication or infection of the uterus) - needs to be investigated further in future trials
	solution s to determin		includes elective laboring	Post op fever, post				

Jakes et	e adverse events associat ed with intervent ion	Quali	and urgent CD	op WI, endometrit is, post op wound seroma or hematoma	SSI	No	12 months	Level of evidence: IV
al., (2020), Impleme ntation of vaginal preparati on prior to caesarea n section	nt VP prior to CD at Guy's and St Thomas' Hospital NHS Foundati on Trust and reduce rates of deep SSIs	ty impro veme nt report	tertiary hospital located in central London Delivered roughly 6800 babies annually, CD rate is 35%	VP is the cleansing of the epithelium with an antibacteri al solution, to reduce ascending genital tract infection VP can be completed with povidone-iodine or	surveillance - in line with public health England recommend ations  Consist of surveillance forms, discharge questionnair e, telephone interviews  Women were telephoned	statistic al analysis possibl e due to small number of women and short timesca le observe d	following VP implementation, SSI rate is lowest recorded in last 6 years	Strengths: Intervention is cheap, simple, and performed with readily available materials, inclusion criteria was expanded with clinical team once intervention was accomplished on >85% women,  Limitations: low level evidence, no data analysis  Conclusion/recommendations:  VP prior to CD has been implemented at Guy's and St  Thomas', involvement of stakeholders were key to success, intervention still being performed, has resulted in a

Kanza, (2021),	Determi ne effect	Rand	3 groups (saline –	chlorhexid ine  SSI – superficial incisional, deep incisional, organ/spac e infections  SP CD within 30 days  IV  VP –	at day 30 post CD with up to 3 attempts to make contact	Data were	VP with normal saline solution or	reduction of SSI, continue SSi surveillance  Level of evidence: II  Strengths: microbiological
The effect of vaginal cleansin g performe d with normal saline solution or povidon	of VP perform ed with solution s before elective CD on PP maternal morbidit y and	d contr olled study	n=60, PI n=60, control group n=60)	cleansing of vaginal walls with solutions to disinfect area  CD – delivery of infant		analyze d with the IBM SPSS V23	PI before CD significantly reduced post-op pain, fever, and CRP levels Cleansing vagina before CD clinically reduced number of post-	measurements were performed Limitations: size of sample was small, only included primiparous women whose labor did not start  Conclusion/recommendation: future studies should be conducted

e-iodine	post-op	via	CD site infections	
before	infection	surgery	and endometritis	
elective		through		
caesarea		abdominal		
n section		incision		
on		DV		
postoper		DV		
ative		Maternal		
maternal		morbidity		
morbidit				
y and		complicati		
infection		ons		
; A		arising		
prospecti		after		
ve		surgical		
randomi		procedure		
zed		of		
controlle		delivering		
d study		baby		
		Post on		
		Post-op infection-		
		infection		
		occurring		
		after		
		surgery		

Kawakit	Examine	Quasi	1,100	Surgical	Outcomes	MedSta	After	Level of evidence: Level III
a et al., (2019), Reducin g cesarean delivery surgical site infection s: a resident-driven quality initiative	associati on of resident driven quality initiative with CD SSI	exper iment al	women CD at 23 weeks GA or greater between 2015- 2018 Excluded emergenc y CD, chorioam nionitis, patients with purulent fluid from cervix	bundle including: antibiotics , skin preparatio n, clippers instead of razors, vaginal cleasing, placenta removal by umbilical cord traction  SSI (superficia l incisional, deep incisional, and organ or space surgical site infections)	were compared in the pre- implementat ion and post- implementat ion phases	r Instituti onal Review Board approve d analysis ,Cochra n-Armita ge Trend test perform ed, Stata/I C 15.1, X2 test variable s and student t-test	implementing surgical bundle, a significant decrease in CD SSI was observed	Strengths: demonstration of successful resident-driven quality initiative, evidence-based bundle approach was standardized and reduced SSI by 50%, SSI defined by objective data  Quality of evidence: high  Limitations: Underestimated number os SSI, Information of a loss of follow up wasn't available, Unable to determine which specific intervention contributed to a reducation in SSI

				up to 6 weeks PP				
Lakhi et al., (2019), Vaginal cleansin g with chlorhex idine gluconat e or povidon e-iodine prior to cesarean delivery: a randomi zed compara tor-controlle d trial	Determine whether VP with chlorhex idine results in fewer WI compare d to PI	Rand omize d, comp arator - contr olled trial	1,114 patient met inclusion criteria (524 to the chlorhexi dine group and 590 to the PI group)  Both groups similar with regard to age, parity, BMI, gestation al age at delivery	IV  CD – delivery of infant through abdomen via incision  VP – disinfectin g vagina walls with solution  DV  SSI – infection that happens post delivery within 30 days (superficia	Follow up phone call for WI occurrence after DC via standard phone telephone interview, calls made 14-20 after DC	Power analysis for a c <sup>2</sup> test was conduct ed in G-POWE R 3.1 (Faul and Erdfeld er)  Student t test or Mann-Whitne y U test Categor ical data was compar ed	Rate of wound infection was significantly lower in the chlorhexidine arm as compared with povidone-iodine	Level of evidence: II  Strengths: no adverse reactions noted,  Limitations: trial used at a single site, blinding not possible due to both solutions being different colors  Conclusion/recommendation: larger sample size is neccessary

			Compute r- generated calendar block randomiz ation method utilized	l and or deep)  Endometri tis — infection effecting tissues  Post-op fever — temp greater or above 100.4F		using c <sup>2</sup> or Fisher exact tests		
Liu et al., (2023), Different methods	Reivew clinical trials and summari	Syste matic revie w and meta-	23 trials including 10,026 CD patient	VP methods include 19 iodine- based	2 reviewers independent ly extracted data and assessed	Statistic al evaluati on perform	Overall VP significantly reduced risks of endometritis, post-op fever and	Level of evidence: Level I  Strengths: systematic analysis of multiple outcomes was conducted, possible biases were
of vaginal preparati on before cesarean delivery to prevent	ze the most suitable VP for CD	analy sis	were included  Excluded non-RCTs, no use of iodine or guanidine	disinfecta nt and 4 guanidine- base disinfecta nts	risk of bias and certainty of evidence, effectivenes s of prevention was assessed by	ed by funnel plot and Egger test, multipl e subgrou	WI	assessed, extensive and systematic literature search was conducted including studies from multiple countries and languages, strict inclusion criteria were used  Limitations: VP methods other than iodine and guanideine based

postoper ative infection : a systemat ic review and			-based disinfecta nts, no reporting of post- op infection outcomes		frrenquentis t-based network meta- analysis models	p abalyse s were perform ed		disinfectants were not used, conclusion of subgroup analysis is limited, different regions differ in certain aspects of surgical procedures  Conclusion/reccomendations: VP reduced the risks of endometritis, post-op fever, and
network meta- analysis								wound infection, 1% poviodone- iodine has outstanding effects
Ogah et al., (2021), Preopera tive vaginal cleansin g with chlorhex idine solution in preventing post-cesarean section infection	Evaluati ng the efficacy of preopera tive VP in reductio n of post-CD infectiou s morbidit ies	Rand omize d contr ol trial	322 pregnant women who underwen t emergenc y CD 2 groups - interventi on and control group	Emergenc y CD – delivery of baby via surgery in an urgent manner  VP – cleaning vagia with chlorhexid ine	Diagonosed endometritis by fever, foul/offensi ve/purulent lochia, uterine fundal tenderness  WI diagnosed by wound erythema, tenderness, purulent drainage	Statistic al packag e for social science softwar e version 22	IM was significantly reduced from 36.8% in control group to 12.0% in intervention group, fever was more common in control group	Level of evidence: II  Strengths: not specified  Limitations: not specified  Conclusion/recommendation: use of chlorhexidine vaginal cleansing in at-risk women undergoing CS prioritize SSI control and surveillance in the study area

s in a low resource setting: a randomi zed controlle d trial				antiseptic solution  DV  Endometri tis  WI	from incision			
Reid et al., (2001), Vaginal preparati on with povidon e iodine and postcesa rean infectiou s morbidit y: A randomi zed controlle d trial	Determine whether VP with povidon e iodine before CS decrease d incidenc e of PP IM	A rando mized contr oll trial	Participa nts were randomly assigned to VP with PI (n= 247) or no preparati on (n=251) No differenc e is maternal age, race, parity, education	CS – delivery of baby via surgical procedure VP – disinfectin g vaginal walls with solutions DV IM – fever, endometrit	One of four physicians, masked to randomizati on assignment, reviewed the admission record and abstracted information	Greater than 80% power to detect such a differen ce if the outcom e investig ated was no more commo n than 23% (two-tailed <sup>2</sup>	VP with PI before CD had no effect on incidence of fever, endometritis, or WI	Level of evidence: II  Strengths: avoiding possible potential to harm  Limitations: Rarity of outcome events, strict definitions may have caused fewer cases of infection, did not seek validation that preparation was done correctly, intent-to-treat analysis  Conclusion/recommendation:Me ta-analysis could clarify association of VP related to infection post-CD, do not assert that VP does not provide benefit

			, payment status	is, wound separation		with 0.05). Analysis was done using Stata Statistic al Softwar e (Stata Corpor ation, College Station, TX)		
Roeckne r et al., (2019), Povidon e-iodine 1% is the most effective vaginal antisepti c for	Compar e efficacy of antisepti c formulat ions used for preparati on of	Syste matic revie w and netwo rk meta-analy sis	23 studies Included RCT with characteri stics of: studies that compared VP	IV vaginal cleansing- utilizing solution to kill bacteria intravagin ally	Computeriz ed software used user- written programs to assess con- sistency, inconsistenc y, ranking probabilities , and	DerSim onian- Laird random effects model Hertero geneity was tested	Presurgical VP with antiseptic solutions reduces infectious morbidity after CD PI was effective at reducing the rate of endometritis,	Level of evidence:Level I  Strengths: use of a network framework for indirect comparisions haven't undergone head-to-head trials, extensive literature search with use of computerized databases, registered review that followed preferred reporting items for systematic review and meta

preventi	vagina	solutions	CD –	graphing	with	wound infection,	anyalysis guidelines, study
ng post-	before	administe	delivery	results	the I2	and PO fever	quality assessment
cesarean	CD	red	of	1034163	index	una 1 0 10 101	quanty assessment
endomet	CD	before	newborn		and the	Various	Limitations: potiontial
ritis:		CD with	baby		Cochra	treatments are	confounding factors and
		aim of	1		ne's Q	available	selection bias, trials varied in
a system			through		_	although PI 1%	techniques of randomization,
atic		reducsing	abdomen,		statistic	appears to be the	Cetrimide and metronidazole
review		post-CS	surgically		Publica	best treatment	had a single study
and		infection,			tion	option	
network		studies			and	opuon	Feasibility of use of evidence
meta-		that	DV		related	VP has been	Conclusion/recommendation:
analysis		compared	F 1		biases	shown to decrease	cost of agents is low, application
		VP	Endometri		were	the number of	time is minimal, reducing
		solutions	tis –		assesse	vaginal organisms	vaginal flora with the use
		with each	infection		d by		vaginal antiseptics is plausible
		other or	of cells		examini		action in reducing endometritis
		against	Infectious				
		placebo	morbidity-		ng funnel		
		or	effects of				
			infection		plots		
			that can		and the		
			lead to		Eggar		
					test		
			other				
			complicati				
			ons				
			Post-op				
			wound				
		1	Woulld				

	infection –		
	infection		
	30 days		
	after		
	surgery		
	Readmissi		
	on- being		
	admitted		
	back into		
	hospital		
	Fever –		
	temp of		
	greater		
	than 100.4		

 $\label{eq:condition} Legend: CS-cesarsean section, CD-cesarsean delivery, VP-vaginal preparation, VC-vaginal cleansing, IM-infectious morbidity, PP-post-partum, PO-preoperative, WI-wound infection, VS-vaginal solution, VE-vaginal exam(s), SSI-surgical site infections, SP-status post, PI-povidone iodine, DC-discharge$ 

# Please do not repeat the headings, just provide the data

Used with permission, © 2007 Fineout-Overholt

# Appendix B

# **Timetable/Flowchart for Implementation**

